3. Discussion
UC is a leading form of bacterial UTI, affecting healthy women with no structural or neurologic urinary tract abnormalities, and can be accompanied by various symptoms, such as frequency, urgency, and dysuria, and has a socioeconomic burden due to frequent recurrences [1,3,4]. In general, UC due to E. coli is simple to treat with oral empiric antibiotics. However, AMR has been rapidly increasing globally [11,15,16,17]; therefore, investigation and monitoring of AMR are essential to select the optimal antibiotics based on the correct antimicrobial susceptibility information in the community. The present study was conducted focusing on the AMR of E. coli in patients with UC, and the results were that fluoroquinolone resistance was 49.1%, and was significantly higher in tertiary hospitals, postmenopausal women, and patients with recurrent cystitis.
Uropathogenic E. coli, a Gram-negative bacillus of the Enterobacterales family, commonly originates from the human gastrointestinal tract and various animals [23,24]. E. coli is the most common pathogenic factor for UTIs, and the prevalence was reported as 70–75% in both adult and pediatric UTIs in previous studies worldwide, and in the present study [9,21,25,26]. The pathogenic process of E. coli in the urinary tract can be explained by several steps: periurethral and vaginal invasion and colonization, ascension into the bladder lumen and growth in the urine, adherence to the surface and interaction with the defensive system of the bladder epithelium, biofilm formation, replication via the formation of intracellular bacterial communities (a source of quiescent intracellular reservoirs), and kidney colonization [9,24]. This process can cause severe sequalae such as recurrent UTIs, bacteremia, septicemia, urosepsis, and even death, despite treatment with empiric antibiotics [27,28]. In fact, at least 30% of patients with UC have a recurrence within 6–12 months, leading to a socioeconomic burden from factors such as a negative impact on the quality of relationships, self-esteem, and capacity for work [8].
The use of antimicrobial agents is the most important approach to the treatment of UTIs, and has significantly reduced mortality and increased life expectancy [12]. However, the persistent failure to develop new antimicrobial agents and the injudicious use of antimicrobials have led to the emergence of AMR [13]. Moreover, the long-term use of antimicrobial agents can promote the gradual alteration of the normal microbiota of the vagina and gastrointestinal tract and the development of multidrug-resistant microorganisms [29]. Indeed, the AMR of bacteria, such as ESBL-producing E. coli and multidrug-resistant bacteria, has been rapidly increasing in recent years and has become a major concern worldwide [11,15,16,17]. Numerous organizations such as the World Economic Forum, the World Health Organization, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America have declared that AMR is a ‘global public health problem’ [18,19]. In addition, a report on the socioeconomic burden of AMR predicts that, in 2050, about 444 million people will experience infections, at a global economic cost of approximately USD 120 trillion [15]. Hence, the appropriate selection and use of optimal antibiotic therapies is imperative to reduce AMR and its effect on socioeconomic burden, and the systemic surveillance of AMR is also crucial. To date, there have been several efforts to improve AMR surveillance: for example, the Global Prevalence of Infections in Urology study from 2005 was a representative, web-based study [20]. In the Republic of Korea, there was a nationwide survey in 2008 for the AMR of urinary isolates in UTIs [21]; this survey has become a good model of the current AMR monitoring system established by KAUTII in 2023. KARMS is an internet-based surveillance system, with input from medical centers nationwide in Korea, and has the advantage that it can be conducted continuously with reduced time and cost. In practice, most major urologic centers in Korea participate in KARMS, so that data can be obtained on regional microbiologic characteristics and corresponding antibiotic susceptibility information. From the KARMS database, the present study was conducted, focusing on the AMR for E. coli in patients with UC.
In the present study, the resistance rates for E. coli to ciprofloxacin and cefotaxime were 49.1% and 17.6%, respectively. These rates were higher than those in a South Korean nationwide survey in 2008: 25% resistance to fluoroquinolones, and 5% resistance to third-generation cephalosporins [21]. Distressingly, in just 15 years, resistance rates to fluoroquinolones and third-generation cephalosporins have approximately doubled and tripled, respectively. In 2008, the prevalence of E. coli was reported as 73%, which is similar to the prevalence of 75% in the present study.
Results from other countries showed that resistance rates for E. coli to fluoroquinolones were significantly higher in developing countries (Nepal 64.6%, Pakistan 60.8%, Mongolia 58.1%, Jordan 55.5%, Ethiopia 85.5%) than in developed countries (USA 5.1%, Germany 10.5%, Switzerland 17.4%, France 24.8%, Japan 18.6%) [22,24]. Compared to other countries, the current fluoroquinolone resistance rate for E. coli in patients with UC in the Republic of Korea has already reached serious levels. Hence, fluoroquinolones should no longer be used as empiric antibiotics for UC. However, fosfomycin and nitrofurantoin can be proposed as reliable empiric antibiotics for UC, based on the low resistance rates to fosfomycin and nitrofurantoin in the present study; this recommendation is consistent with recent studies and guideline recommendations for the clinical and microbiologic treatment of UC [30].
In the present study, AMR rates for E. coli to fluoroquinolones and third-generation cephalosporins were evaluated according to clinical factors, such as hospital region and type, menopausal status, and recurrence status. Regarding hospital region, no significant differences were observed. However, regarding other clinical factors, fluoroquinolone resistance was significantly higher in tertiary hospitals (primary 31.7%, secondary 47.1%, tertiary 57.8%), postmenopausal women (premenopausal 30.6%, postmenopausal 54.2%), and patients with recurrent cystitis (non-recurrence 41.0%, recurrence 70.3%; p < 0.001); all these factors were associated with increased fluoroquinolone resistance. Of note, fluoroquinolone resistance in patients with recurrent cystitis was extremely high, at 70.3%, which means that fluoroquinolones should no longer be used in these patients. In addition, resistance to third-generation cephalosporins was significantly higher in tertiary hospitals (primary 11.3%, secondary 17.1%, tertiary 23.0%) and postmenopausal women (premenopausal 12.6%, postmenopausal 19.6%). These significant differences have several explanations. For example, lower levels of estrogen at menopause lead to adverse changes in the urogenital epithelium and urogenital microbiome by reducing urothelial thickness and an abundance of tight-junction proteins, which can promote pathogen colonization via impaired urothelial defense mechanisms [31]. Multiple and long-term use of antibiotics in patients with recurrent cystitis increases AMR via dysbiosis induced by the breakdown of microbiota homeostasis and quiescent intracellular reservoirs formed by infected intracellular bacterial communities [29]. Also, many patients in tertiary hospitals, compared to other types of hospitals, are postmenopausal women and patients with recurrent cystitis.
In a detailed analysis, the rates of fluoroquinolone resistance in premenopausal and postmenopausal women in the Republic of Korea were 30.6% and 54.2%, respectively. Compared to the results of a recent Japanese study, [22] the South Korean results showed 3-fold higher rates in premenopausal women and 22% higher rates in postmenopausal women. Even considering the differences in the representative types of fluoroquinolones used in the two countries (Korea: ciprofloxacin, Japan: levofloxacin), the present study showed that fluoroquinolone resistance in Korea is incredibly high. Conversely, resistance rates to third-generation cephalosporins in premenopausal and postmenopausal women in Korea were 12.6% and 19.6%, respectively, and there were no significant differences compared to the recent Japanese study [22].
ESBL-producing Gram-negative bacteria have gradually increased in prevalence and have now become endemic worldwide, in part as a consequence of the use, abuse, and misuse of β-lactam antibiotics. In general, ESBL-producing E. coli are resistant to most β-lactam antibiotics, including extended-spectrum cephalosporins and monobactams, and are commonly identified in both community-acquired infections and healthcare-associated infections [32]. The prevalence of ESBL-producing E. coli has been reported as 8–30%, according to geographic location, and their prevalence in the Asia–Pacific region has been reported as 17.4% [11]. In the present study, ESBL positivity was 14.4%, and was significantly higher in tertiary hospitals (primary 7.8%, secondary 13.8%, tertiary 24.6%) and patients with recurrent cystitis (non-recurrence 12.4%, recurrence 27.6%); both factors were associated with increased ESBL positivity. These significant differences can be explained by the distribution of patients according to hospital type, and age- or infection-related hormonal, mechanical, and physiological alterations [29,31].
The results of the present study indicate that the AMR of E. coli in patients with UC in the Republic of Korea has reached a serious level, especially regarding fluoroquinolone resistance. Although there are many contributing factors to increasing AMR, probably the most important are the injudicious use of antibiotics, and nonadherence to local, national, or international guidelines. In a survey of actual treatment practices for patients with UC in Korea, 28% of urologists had not performed a urine culture at initial treatment, and 54% had not performed a urine culture, even in cases of initial treatment failure. In addition, the most commonly prescribed antibiotics were second- or third-generation cephalosporins and fluoroquinolones, contrary to guideline recommendations for the use of fosfomycin or nitrofurantoin [4,33].
In the present study, the rate of resistance to third-generation cephalosporins was high. If this trend continues, the rate of resistance to third-generation cephalosporins will eventually reach a serious level, like the rate of resistance to fluoroquinolones. Hence, antimicrobial stewardship is required to reduce AMR. The goal of antimicrobial stewardship is to optimize clinical outcomes and ensure cost-effective therapy while minimizing unintended consequences of antimicrobial use [34]. Antimicrobial stewardship consists of a few programs: regular training of staff in the best use of antimicrobial agents; adherence to local, national, or international guidelines; audits of adherence and treatment outcomes; regular monitoring and feedback to prescribers of their performance; and local pathogen resistance [35]. Moreover, antimicrobial stewardship promotes increased adherence to antibiotic policy, leading to reduced antibiotic treatment duration and a reduced relative risk of mortality [35]. Therefore, major efforts should be made to establish antimicrobial stewardship along with AMR surveillance in the Republic of Korea.
The present study has some limitations. First, although this was an internet-based, prospective, multicenter, and national observational survey, there may have been a selection bias due to a variable number of patients included by hospital region and type. Second, the methodology used to identify E. coli and antimicrobial susceptibility was not unified. However, all tests performed at participating institutions were approved by the microbial standards of each institution, and antimicrobial susceptibility was investigated according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI) [36,37,38]. Third, data entry into the website may have been influenced by inter-investigator bias.
Nevertheless, the present study has some possibilities and strengths. In circumstances where AMR has emerged as a one of the greatest threats to global health, the present study provides important information on the AMR status of E. coli in patients with UC in the Republic of Korea, which can help clinicians to understand the severity of AMR and avoid the injudicious use of antibiotics. Also, the continuous monitoring and accumulation of data enables the identification of changing AMR patterns over time and comparisons with other antimicrobial monitoring systems. In addition, our data can provide the evidence base for future antimicrobial treatment guidelines for UTIs.
CC BY 4.0. "Antimicrobial Resistance of Escherichia coli for Uncomplicated Cystitis: Korean Antimicrobial Resistance Monitoring System" by Yu SH, Jung SI, Lee SJ et al., Antibiotics (Basel, Switzerland) (2024). https://doi.org/10.3390/antibiotics13111075. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Peer-reviewed and open access; full text from PubMed Central (PMC11591001). Headings and layout adapted for reading; figures and tables are in the original.